Faculty Information |
|
Language | Japanese |
The announcement title | A prospective observational study for real-world drug therapy of advanced renal cell carcinoma |
Academic Society name | The 110th Annual Meeting of the Japanese Urological Association |
Conference Type | Domestic Society |
Announcement form | Oral presentation |
Presentation Type | General Lecture |
Lecture Type | 一般 |
Date | 2023/04/20 |
Country | Japan |
Holding period | 2023/04/20~2023/04/23 |
Society abstract | OP23-02 2023 |
Description | We performed a prospective observational study for real-world drug therapy of advanced renal cell carcinoma (aRCC) in the era before combined immunotherapy was approved as a first-line treatment for aRCC. The candidates ware patients with aRCC in treatment with molecular targeted agents, without previous treatment history with immune checkpoint inhibitors. Patients in treatment with molecular targeted agents as pre-surgical adjuvant therapy scheduled for cytoreductive nephrectomy were excluded. Registration period was from March, 2017 to August, 2019. Patients were cumulatively enrolled in 13 medical centers participated in Osaka Urology Research Foundation. Patient characteristics included age, MSKCC and IMDC risk, histological type, metastatic site, coexisting illness, and treatment history. Surveyed were treatment duration, objective response, time to response, and progression-free survival for each treatment agent, and overall survival. Adverse events were recorded based on CTCAE version 4.0. Data on total 329 patients will be reported. |